Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.40 per share
-
Shares outstanding
-
23.6M
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
168M
-
Shares change
-
-10.3M
-
Total reported value, excl. options
-
$395M
-
Value change
-
-$37.1M
-
Number of buys
-
50
-
Number of sells
-
-43
-
Price
-
$2.35
Significant Holders of Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) as of Q4 2024
123 filings reported holding AUTL - Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share as of Q4 2024.
Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 168M shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (25.3M shares), Blackstone Inc. (20.5M shares), Syncona Portfolio Ltd (16.6M shares), FMR LLC (15.6M shares), Deep Track Capital, LP (14.2M shares), Avoro Capital Advisors LLC (9.91M shares), ARMISTICE CAPITAL, LLC (9.2M shares), TFG Asset Management GP Ltd (8.25M shares), Frazier Life Sciences Management, L.P. (4.62M shares), and Affinity Asset Advisors, LLC (4.5M shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.